Last mentioned: Jul 16, 2026
Across the most recent 5 stories covering FDA — 80% positive, 20% negative sentiment, averaging 7/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Market Outperformance
Grail shares surge as market sentiment shifts from bearish to bullish, leading the biotech sector gains.
TD Cowen Upgrade
Analysts upgrade GRAL, calling the recent selloff a 'buying opportunity' and stabilizing the stock price.
Leadership & Trial Volatility
CEO Bob Ragusa announces retirement; reports surface regarding a setback in the NHS-Galleri clinical trial.
The biotech venture market is splitting in two: established clinical-stage companies are raising megafunds at a blistering pace, while preclinical and seed-stage biotechs face a deepening funding winter. The contrast underscores a structural shift in startup financing strategies.
After a volatile start to March marked by a CEO transition and clinical trial setbacks, Grail (GRAL) shares staged a massive recovery this week. The rebound was fueled by a high-profile analyst upgrade and a market correction following what many saw as an overreaction to recent headwinds.
The U.S. Food and Drug Administration is introducing a performance-based bonus system to reward staffers who complete drug reviews ahead of schedule. This regulatory shift aims to clear backlogs and could significantly shorten the path to market for biotech startups and their venture backers.
The FDA has proposed a groundbreaking regulatory system designed to streamline the approval of customized, 'N-of-1' therapies for ultra-rare diseases. This shift marks a transition from traditional mass-market drug evaluation to a platform-based approach, potentially unlocking significant venture investment in precision medicine.
Amai Proteins has received FDA GRAS approval for its designer protein sweetener, Sweelin, marking a pivotal regulatory milestone for the precision fermentation industry. This clearance allows the Israeli food-tech startup to begin large-scale commercialization in the U.S. food and beverage market.
This page surfaces every story mentioning FDA across our startup coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running startup beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where FDA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |